Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
DateTitle  
09/14/16Allergan to Acquire Vitae Pharmaceuticals Adding Innovative Development Programs for Dermatologic Conditions
- Acquisition Adds Differentiated Development Programs to Strengthen Allergan's Medical Dermatology Pipeline - - VTP-43742, First-in-Class Oral RORγt Inhibitor for Potential Treatment of Psoriasis, Other Autoimmune Disorders - - VTP-38543, Topical LXRβ Agonist, Unique Mechanism of Action for Potential Treatment of Atopic Dermatitis - - Vitae's Contour Drug Discovery Platform and Team Bolsters Allergan's Discovery Research Capabilities - DUBLIN and FORT WASHINGTON, Pa., Sept.... 
Download PDFPrinter Friendly Version
09/01/16Vitae Pharmaceuticals to Present at Wells Fargo Healthcare Conference
FORT WASHINGTON, Pa., Sept. 01, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the 2016 Wells Fargo Securities Healthcare Conference on Thursday, September 8, 2016 at 1:10 p.m. EDT at the Westin Boston Waterfront. A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae w... 
Download PDFPrinter Friendly Version
08/11/16Vitae Pharmaceuticals to Present at Wedbush PacGrow Healthcare Conference
FORT WASHINGTON, Pa., Aug. 11, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Jeffrey Hatfield, President and Chief Executive Officer, will present a company overview at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17, 2016 at 9:45 a.m. EDT at the Le Parker Meridien New York. A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae website... 
Download PDFPrinter Friendly Version
08/10/16Vitae Pharmaceuticals Appoints Scott Applebaum as General Counsel and Corporate Secretary
FORT WASHINGTON, Pa., Aug. 10, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of Scott Applebaum as General Counsel and Corporate Secretary, effective immediately. Mr. Applebaum most recently served as Chief Legal Officer and Corporate Secretary at Medgenics, Inc., a genomics medicine company focused on rare pediatric diseases. “Scott’s extensive experience in providing legal and corporate complianc... 
Download PDFPrinter Friendly Version
08/03/16Vitae Pharmaceuticals Reports Second Quarter 2016 Operating and Financial Results
Proof-of-concept data for VTP-38543 expected in the fourth quarter of 2016 Conference call scheduled for 4:30 p.m. EDT today FORT WASHINGTON, Pa., Aug. 03, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today reported its operating and financial results for the quarter ended June 30, 2016. Jeff Hatfield, President and Chief Executive Officer of Vitae, commented, “During the quarter, we made significant progress towards the comple... 
Download PDFPrinter Friendly Version
08/01/16Vitae Pharmaceuticals to Announce Second Quarter 2016 Financial Results on August 3, 2016
FORT WASHINGTON, Pa., Aug. 01, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Wednesday, August 3, 2016 at 4:30 p.m. EDT to discuss second quarter 2016 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the conference ID 56375... 
Download PDFPrinter Friendly Version
07/27/16Vitae Pharmaceuticals Appoints Daniel M. Junius to Board of Directors
Bryan Roberts, Ph.D. steps down from board FORT WASHINGTON, Pa., July 27, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the appointment of Daniel M. Junius to its board of directors, effective immediately. Mr. Junius recently retired as President and Chief Executive Officer of ImmunoGen, Inc., a biotechnology company that develops targeted anticancer therapeutics, a position he held since January 2009. “On behalf... 
Download PDFPrinter Friendly Version
06/14/16Vitae Pharmaceuticals to Present at JMP Securities Life Sciences Conference
FORT WASHINGTON, Pa., June 14, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Richard Gregg, M.D., Chief Scientific Officer, will present a company overview at the JMP Securities Life Sciences Conference on Tuesday, June 21, 2016 at 1:00 p.m. EDT at the St. Regis New York. A live audio webcast of the presentation will be available via the "Investor Relations" page of the Vitae website, www.vitaepharma.com. A r... 
Download PDFPrinter Friendly Version
06/06/16Vitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer
FORT WASHINGTON, Pa., June 06, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Carole Sable, M.D., has been named Chief Medical Officer, effective immediately. Dr. Sable will oversee the clinical development of Vitae’s pipeline, including wholly owned mid-stage clinical assets VTP-43742, an oral RORyt inhibitor being developed for autoimmune disorders and currently being assessed in moderate to severe psoriasis, a... 
Download PDFPrinter Friendly Version
05/10/16Vitae Pharmaceuticals Reports First Quarter 2016 Operating and Financial Results
Proof-of-concept data for VTP-38543 expected in the second half of 2016 Conference call scheduled for 4:30 p.m. EDT today FORT WASHINGTON, Pa., May 10, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today reported its operating and financial results for the quarter ended March 31, 2016. Jeff Hatfield, President and Chief Executive Officer of Vitae, commented, “The highlight of the first quarter was the positive top-line results ... 
Download PDFPrinter Friendly Version
05/09/16Vitae Pharmaceuticals to Present at IMMUNOLOGY 2016
Poster to highlight positive Phase 1 data for RORγt inhibitor VTP-43742 FORT WASHINGTON, Pa., May 09, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Gerard M. McGeehan, Ph.D., Vice President of Biology, will present a poster titled “Safety, tolerability, pharmacokinetics and pharmacodynamics of VTP-43742, a RORγt inhibitor, in normal healthy volunteers” at IMMUNOLOGY 2016, the American Association of Immunolog... 
Download PDFPrinter Friendly Version
05/03/16Vitae Pharmaceuticals to Announce First Quarter 2016 Financial Results on May 10, 2016
FORT WASHINGTON, Pa., May 03, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Tuesday, May 10, 2016 at 4:30 p.m. EDT to discuss first quarter 2016 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the conference ID 1781961 fiv... 
Download PDFPrinter Friendly Version
03/30/16Vitae Pharmaceuticals Closes Public Offering of Common Stock
FORT WASHINGTON, Pa., March 30, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the completion of its underwritten public offering of 5,833,333 shares of its common stock at a price to the public of $6.00 per share. In connection with the offering, Vitae has granted the underwriters a 30-day option to purchase up to an additional 875,000 shares of its common stock on the same terms and conditions. The gross offering pr... 
Download PDFPrinter Friendly Version
03/24/16Vitae Pharmaceuticals Prices Public Offering of Common Stock
FORT WASHINGTON, Pa., March 24, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced the pricing of an underwritten public offering of 5,833,333 shares of its common stock at a price to the public of $6.00 per share. In connection with the offering, Vitae has granted the underwriters a 30-day option to purchase up to an additional 875,000 shares of its common stock on the same terms and conditions. Gross proceeds from the s... 
Download PDFPrinter Friendly Version
03/23/16Vitae Pharmaceuticals Proposes Public Offering of Common Stock
FORT WASHINGTON, Pa., March 23, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) (Vitae), a clinical-stage biotechnology company, today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. All of the shares in the offering are to be sold by Vitae, with net proceeds to be used to advance the clinical development of Vitae’s RORγt program, including, among other items, the completion of a 16-week Phase 2b clinical trial of VT... 
Download PDFPrinter Friendly Version
03/16/16Vitae Pharmaceuticals Achieves Proof-of-Concept with First-in-Class RORyt Inhibitor in Moderate to Severe Psoriasis
VTP-43742 demonstrated statistically significant efficacy and was well tolerated              Company plans to move VTP-43742 forward into 16-week study Conference call to discuss results at 5:00 p.m. ET, March 16, 2016 James Krueger, M.D., Ph.D., Head of the Laboratory for Investigative Dermatology at Rockefeller University, to join call FORT WASHINGTON, Pa., March 16, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announ... 
Download PDFPrinter Friendly Version
03/03/16Vitae Pharmaceuticals Reports Fourth Quarter and Full Year 2015 Operating and Financial Results
Proof-of-concept data for VTP-43742 expected in the first quarter of 2016 Initiated proof-of-concept trial of VTP-38543 in patients with atopic dermatitis Conference call scheduled for 4:30 p.m. EST today FORT WASHINGTON, Pa., March 03, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today reported its operating and financial results for the fourth quarter and full year ended December 31, 2015. Jeff Hatfield, President and Chief E... 
Download PDFPrinter Friendly Version
02/25/16Vitae Pharmaceuticals to Announce Fourth Quarter and Full Year 2015 Financial Results on March 3, 2016
FORT WASHINGTON, Pa., Feb. 25, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, will host a conference call on Thursday, March 3, 2016 at 4:30 p.m. EST to discuss fourth quarter and full year 2015 financial results and recent operational highlights. A question-and-answer session will follow Vitae's remarks. To participate on the live call, please dial 844-423-9893 (domestic) or +1-716-247-5808 (international) and provide the confere... 
Download PDFPrinter Friendly Version